Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q12852

UPID:
M3K12_HUMAN

ALTERNATIVE NAMES:
Dual leucine zipper bearing kinase; Leucine-zipper protein kinase; MAPK-upstream kinase; Mixed lineage kinase

ALTERNATIVE UPACC:
Q12852; B3KSS9; G3V1Y2; Q86VQ5; Q8WY25

BACKGROUND:
The protein Mitogen-activated protein kinase kinase kinase 12, with alternative names such as Leucine-zipper protein kinase and MAPK-upstream kinase, is integral to a specialized MAPK signaling pathway. Triggered by APOE, it facilitates AP-1's transcriptional activity on APP via a pathway comprising MAP2K7, MAPK1/ERK2, and MAPK3/ERK1, potentially activating the JNK/SAPK pathway as well.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Mitogen-activated protein kinase kinase kinase 12 offers a promising avenue for developing novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.